课题基金 / 基金详情

NEUROBIOLOGY OF DISRUPTIVE BEHAVIOR DISORDERS

NEUROBIOLOGY OF DISRUPTIVE BEHAVIOR DISORDERS
破坏性行为障碍的神经生物学
批准号:
3921958
负责人:
J L RAPOPORT
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

J L RAPOPORT的其他基金

相似基金

相关文献

中文摘要
翻译
攻击行为维度之间的关系, 冲动性和单胺代谢物浓度, 尤其是儿童脑脊液中的5-HIAA 儿童时期的破坏性行为障碍正在接受检查。AS 作为研究的一部分,脊髓液中的方法学变量 对儿童的研究正在得到澄清。衡量社会-- 正在进行环境变量的评估 家庭环境与5-羟色胺能指标的关系 关于测量预测有效性的后续研究 正在对儿童和青少年进行脑脊液5-HIAA的研究。 为探讨5-羟色胺在ADD病理生理学中的作用, 20名多动儿给予芬氟拉明(0.6-2.0 mg/kg), 右旋苯丙胺或安慰剂的双盲交叉研究。 芬氟拉明没有任何行为影响。然而, 显著的生化变化(尿和血浆MHPG降低, 降低尿NE、E和VMA)。中枢5-羟色胺能效应 从血浆催乳素升高和降低推断 血小板5-羟色胺。尽管它的结构类似于 安非他明,芬氟拉明几乎没有治疗作用 效果。
英文摘要
The relationships between behavioral dimensions of aggression, impulsivity, and concentrations of monoamine metabolites, particularly 5-HIAA, in the spinal fluid of children with disruptive behavior disorders of childhood are being examined. As part of that investigation, methodologic variables in spinal fluid studies of children are being clarified. Measurement of socio- environmental variables is being carried out to assess the relations between family environment and serotonenergic measures. Follow-up study to address the predictive validity of measurement of CSF 5-HIAA in children and adolescents is underway. To investigate the role of serotonin in the pathophysiology of ADD, 20 hyperactive boys received fenfluramine (0.6-2.0 mg/kg), dextroamphetamine or placebo in a double-blind crossover study. Fenfluramine had no behavioral effect whatsoever. However, striking biochemical changes (decreased urinary and plasma MHPG, decreased urinary NE, E and VMA). Central serotonergic effects were inferred from the increased plasma prolactin and decreased platelet serotonin. In spite of its structural similarly to amphetamine, fenfluramine has virtually noen of its therapeutic effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DIAGNOSIS IN CHILD PSYCHIATRY
EVALUATION AND TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND RELATED DISORDERS
CHILDHOOD ONSET SCHIZOPHRENIA
BRAIN STRUCTURE AND FUNCTION IN DEVELOPMENTAL NEUROPSYCHOLOGICAL DISORDERS
海外基金